Cancer patients with Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) will be treated with Low Molecular Weight Heparin (LMWH) and apixaban. Study duration is 12 weeks.
Cancer patients who have developed blood clot in the arm that has the central venous catheter will be treated with standard of care blood thinning injection of low molecular weight heparin for 1 week and then for apixaban 5 mg twice daily for the rest of 11 weeks. Data will be collected to see if the central venous catheter "survived" or remained in place and did not have to be taken out because of the clot.
Study Type
OBSERVATIONAL
Enrollment
70
Patients will be treated with Low Molecular Weight Heparin (LMWH) for 1 week and then with apixaban 5 milligram (mg) twice daily for 11 weeks.
London Health Science Center, Victoria Hospital
London, Ontario, Canada
RECRUITINGOttawa Hospital Research Institute
Ottawa, Ontario, Canada
RECRUITINGCentral Line Failure
Infusion failure that does not respond to 2 milligram (mg) tissue Plasminogen Activator (tPA)
Time frame: within 3 months of study follow-up
Recurrent Venous Thromboembolism (VTE)
recurrence of blood clot either in leg or lung or both
Time frame: within 3 months of study follow-up
Bleeding
Major bleeding, clinically relevant minor bleed, death, time to central line failure
Time frame: within 3 months of study follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.